News
-
-
COMMUNIQUÉ DE PRESSE
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
NanoViricides reports NV-387 shows strong orthopoxvirus activity against Smallpox/Mpox via inhalation and skin transmission. Study highlights efficacy in lethal animal models, supporting clinical development potential -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
NanoViricides reports successful completion of Phase I Clinical Trial of NV-387, progresses towards Phase II discussion with physicians and experts for dosing protocol determination -
COMMUNIQUÉ DE PRESSE
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
NanoViricides, Inc. files Quarterly Report on Form 10-Q with SEC, reports financial status and cash balance of $5.31 Million. Company makes strategic moves to improve liquidity and prepares for Phase II clinical trials -
COMMUNIQUÉ DE PRESSE
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
NanoViricides, Inc. reports on the strong safety and tolerability of NV-CoV-2 oral drug products, showcasing their potential for long-term success and broad-spectrum antiviral capabilities, including against RSV and Smallpox-like viruses
